ARA-290

• Form: Lyophilized powder

• Purity: >99%

Overview

ARA-290, also known as cibinetide and helix B surface peptide (HBSP), is an 11–amino acid chain derived from the beta domain of erythropoietin (EPO). Unlike full EPO, which primarily stimulates red blood cell production, ARA-290 was developed to investigate tissue regeneration, repair, and anti-inflammatory activity without hematopoietic effects.

Research Background

ARA-290 is thought to act on the tissue-protective receptor (TPR), also called the innate repair receptor (IRR), a complex of CD131 and part of the EPO receptor. By binding to this receptor, ARA-290 may initiate regenerative and anti-nociceptive pathways without promoting erythropoiesis. Researchers suggest it may modulate pain signaling, inflammation, and cellular repair processes.

Mechanism of Interest

• Nociception: Studies indicate ARA-290 may attenuate nerve pain (allodynia) by modulating TRPV1 channels, reducing sensitivity to capsaicin-induced activation in murine models.

• Anti-inflammatory effects: Experimental findings suggest ARA-290 may lower pro-inflammatory cytokines (IL-1β, TNF-α) and influence microglial activity in models of retinal ischemia.

• Vascular protection: Research indicates potential protection of endothelial cells and enhanced vascular repair capacity when paired with endothelial colony-forming cells (ECFCs) in ischemic retinopathy models.

Scientific Studies

Preclinical research has explored ARA-290 in multiple areas:

• Murine neural studies: Demonstrated potential to reduce capsaicin-induced nociceptive signaling via TRPV1 inhibition.

• Pain modulation: In vivo studies reported reduced sensitivity and fewer nociceptive responses after capsaicin challenge.

• Retinal ischemia: Suggested possible benefits for vascular repair and inflammation control in oxygen-induced retinopathy models.

Molecular Information

• Molecular Formula: C51H54N16O21

• Molecular Weight: 1257.3 g/mol

• Other Names: Cibinetide, HBSP, PH-BSP